LFA-REAL aims to improve health and quality of life for people with lupus.
People with lupus need and deserve a full arsenal of treatments. With many new and innovative drugs for lupus in the drug pipeline, these highly anticipated treatments will mean nothing if people with lupus cannot afford them.
Statement from Sandra C. Raymond, President and CEO of the Lupus Foundation of America
Foundation-funded research studies highlighted at premier rheumatology meeting in Boston.
Award is the largest amount allocated to lupus since 2006
Lupus Foundation of America supported study demonstrates that blocking STAT5 reduces the production of CD154 by half.
Adolescent-onset lupus has worse prognosis and increased risk of lupus-related kidney disease and death.
Sandra C. Raymond, President & CEO of the Lupus Foundation of America, issued the following statement in response to Eli Lilly and Company’s announcement of the results of two Phase III clinical trials of tabalumab.